Article
KRASG 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening.
Molecular oncology - 1 Feb 2025
Tapia Contreras Constanza, Falke Jonas Dominik, Seifert Dana-Magdalena, Schneider Carolin, Krauß Lukas, Fang Xin, Müller Denise, Demirdizen Engin, Spitzner Melanie, De Oliveira Tiago, Schneeweis Christian, Gaedcke Jochen, Kaulfuß Silke, Mirzakhani Kimia, Wollnik Bernd, Conrads Karly, Beißbarth Tim, Salinas Gabriela, Hügel Jonas, Beyer Nils, Rheinländer Sophia, Sax Ulrich, Wirth Matthias, Conradi Lena-Christin, Reichert Maximilian, Ellenrieder Volker, Ströbel Philipp, Ghadimi Michael, Grade Marian, Saur Dieter, Hessmann Elisabeth, Schneider Günter
Abstract excerpt
Pancreatic ductal adenocarcinoma (PDAC) has limited treatment options, emphasizing the urgent need for effective therapies. The predominant driver in PDAC is mutated KRAS proto-oncogene, KRA, present in 90% of patients. The emergence of direct KRAS inhibitors presents a promising avenue for treatment, particularly those targeting the KRASG12C mutated allele, which show encouraging results in clinical trials....
Topics
Join the communities discussing this publication.